To include your compound in the COVID-19 Resource Center, submit it here.

Maturing therapeutic vaccines

Last week, IDM (Paris, France) and partner Sanofi-Synthélabo SA (Paris, France) started a 60-patient European Phase II trial of Uvidem to treat melanoma. The 20-week trial will compare vaccine containing normal dendritic cells with vaccine containing mature dendritic

Read the full 380 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers